Comparison of Dihydroartemisinin-Piperaquine versus Sulphadoxine-Pyrimethamine for malaria prevention in pregnancy

Not Applicable

Recruiting

• Conditions: Malaria; Pregnancy and Childbirth; malaria prevention during pregnancy

• Registration Number: PACTR201808204807776
• Lead Sponsor: Federal Teaching Hospital Abakaliki

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-08-04
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: Female
• Target Recruitment: 360

Inclusion Criteria

1.Pregnant women between 14 weeks and 24 weeks gestation with viable pregnancy.
2.Women who have not received intermittent preventive treatment with sulphadoxine–pyrimethamine during the index pregnancy.
3.Women not allergic to sulphadoxine-pyrimethamine or dihydroartemisinin-piperaquine.
4.Women willing to deliver in the study hospital.

Exclusion Criteria

1.Women in the first trimester of pregnancy.
2.HIV positive pregnant women
3.Women allergic to sulphadoxine-pyrimethamine or dihydroartemisini-piperaquine.
4.Women with high-risk pregnancies e.g. medical diseases in pregnancy (sickle cell disease, diabetes mellitus, hypertensive disorders in pregnancy) and multiple gestations.
5.Women who do not consent to the study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
prevalence of placental malaria

Secondary Outcome Measures

Name	Time	Method
Incidence of symptomatic malaria, adverse birth outcomes, including spontaneous abortion, stillbirth, low birth weight (<2500 g), and preterm delivery (<37 weeks).